2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-112790
    Adenosylcobalamin 13870-90-1 99.15%
    Adenosylcobalamin (Coenzyme B12;Cobamamide;AdoCbl) is an active form of Vitamin B12 which is a cofactor for methylmalonyl CoA mutase
    Adenosylcobalamin
  • HY-142035
    N-Propargylglycine 58160-95-5 99.70%
    N-Propargylglycine is a brain-penetrant and orally active PRODH inhibitor. N-Propargylglycine covalently modifies enzyme-bound FAD and active site lysine, causing enzyme structural distortion, protein decay, and irreversible inhibition of proline and 4-hydroxyproline catabolism. N-Propargylglycine induces UPRmt, upregulates mitochondrial chaperones and YME1L1, enhances mitochondrial proteostasis, blocks astrocytic L-proline consumption, and abolishes L-proline’s ATP-maintaining and viability-protective effects. N-Propargylglycine stimulates neural processes, increases brain proline, hydroxyproline, and sarcosine levels, partially normalizes Huntington’s disease whole brain transcriptomes. N-Propargylglycine reduces hyperoxaluria, prevents calcium oxalate stone formation, reduces kidney tubular damage, and restores weight and survival in Grhpr knockout mice. N-Propargylglycine can be used for the research of breast cancer, neurodegenerative disorders, Huntington’s disease, and primary hyperoxaluria type 2.
    N-Propargylglycine
  • HY-W015924
    2-Hydroxyisobutyric acid 594-61-6 ≥98.0%
    2-Hydroxyisobutyric acid (2-HIBA) is a selective modulator of the Insulin/IGF-1 pathway and the p38 MAPK pathway, which reduces reactive oxygen species (ROS) and fat accumulation in Caenorhabditis elegans. 2-Hydroxyisobutyric acid promotes β-oxidation and inhibits fatty acid synthesis by upregulating SKN-1/NRF2 and downregulating SREBP-1c transcription factors. 2-Hydroxyisobutyric acid has anti-aging and lipid-lowering effects, and can be used to study metabolic diseases such as obesity and diabetes. 2-Hydroxyisobutyric acid is also a renewable precursor of methacrylate through 2-HIB-CoA mutase-mediated biosynthesis[1][2].
    2-Hydroxyisobutyric acid
  • HY-13076
    CHIR-98014 252935-94-7 98.44%
    CHIR-98014 is a potent, cell-permeable GSK-3 inhibitor with IC50s of 0.65 and 0.58 nM for GSK-3α and GSK-3β, respectively; it shows less potent activities against cdc2 and erk2.
    CHIR-98014
  • HY-N0324S
    Cholic acid-d4 116380-66-6
    Cholic acid-d4 is the deuterium labeled Cholic acid. Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.
    Cholic acid-d4
  • HY-N8518
    Malabaricone C 63335-25-1 99.46%
    Malabaricone C is an orally active and noncompetitive sphingomyelin synthase (SMS) inhibitor with IC50 values of 3 μM and 1.5 μM for SMS 1 and SMS 2, respectively. Malabaricone C reduces body weight gain, improves glucose tolerance, and decreases lipid accumulation in the liver, showing significant prevention of high fat diet-induced fatty liver in mice. Malabaricone C has anti-inflammatory effects, which is found in the fruits of Myristica cinnamomea King. Malabaricone C is promising for research of obesity and immunological disorders caused due to hyper-activation of T-cells.
    Malabaricone C
  • HY-107928
    Iron dextran 9004-66-4
    Iron dextran (Fe dextran) can be used in the study of iron-deficiency anemia in animals.
    Iron dextran
  • HY-113263
    17a-Hydroxypregnenolone 387-79-1 99.61%
    17a-Hydroxypregnenolone (17-OHP5) is a metabolite of Pregnenolone (HY-B0151) and a precursor in the biosynthesis of Dehydroepiandrosterone (HY-14650). 17a-Hydroxypregnenolone is a substrate for the enzyme 3β-hydroxysteroid dehydrogenase (3β-HSD).
    17a-Hydroxypregnenolone
  • HY-148104
    ACSS2-IN-2 2332820-04-7 99.49%
    ACSS2-IN-2 is an acyl-CoA synthetase short-chain family member 2 (ACSS2) inhibitor. ACSS2-IN-2 can inhibit ACSS2 activity with an IC50 value of 3.8 nM. ACSS2-IN-2 can be used for the research of several diseases, such as viral infection, metabolic disorders, neuropsychiatric diseases, inflammatory/autoimmune conditions and cancer.
    ACSS2-IN-2
  • HY-157189
    GPR132 antagonist 1 898211-21-7 99.72%
    GPR132 antagonist 1 (GPR132-B-160, Compound 25) is a GPR132 antagonist with an EC50 value of 0.075 μM. GPR132 antagonist 1 has promote insulin secretion activity with an EC50 value of 0.7 μM.
    GPR132 antagonist 1
  • HY-P10746
    EB1002 2770688-48-5 99.98%
    EB1002 is a highly selective, long-acting NK2R agonist. EB1002 exerts central appetite suppression, increases peripheral energy expenditure and enhances insulin sensitivity, which effectively reduces body weight, improves glucose and lipid metabolism, with favorable safety profiles. EB1002 can be used for research on diseases such as obesity and type 2 diabetes.
    EB1002
  • HY-N1446S2
    Oleic acid-13C18 287100-82-7 99.90%
    Oleic acid-13C18 is the 13C labeled Oleic acid (HY-N1446). Oleic acid (9-cis-Octadecenoic acid) is an abundant monounsaturated fatty acid. Oleic acid is a Na+/K+ ATPase activator.
    Oleic acid-13C18
  • HY-W145667
    Mannan 9036-88-8 98.4%
    Mannan is an orally active polysaccharide compound that binds to the mannose receptor (MR). Mannan promotes bacterial uptake and endosomal degradation by binding to MR, thereby enhancing the production of IL-12 in immune cells. Mannan enhances ROS production. Mannan modulates immunity, inhibits Aflatoxin B1 (HY-N6615)-induced toxicity, and reduces lipid.
    Mannan
  • HY-B1472
    Deoxycorticosterone acetate 56-47-3 99.87%
    Deoxycorticosterone acetate (DOCA) is an adrenocortin, acts as a precursor to aldosterone. Deoxycorticosterone acetate is a mineralocorticoid receptor agonist. Deoxycorticosterone acetate can cause severe renal injury, including inflammation, fibrosis, glomerular damage, and proteinuria.
    Deoxycorticosterone acetate
  • HY-N0623R
    L-Tryptophan (standard) 73-22-3 99.98%
    L-Tryptophan (standard) is the analytical standard of L-Tryptophan. L-Tryptophan (Tryptophan) is an orally active and essential amino acid that is the precursor of serotonin, melatonin, and vitamin B3. L-Tryptophan can promote an increase in stemness and osteogenic ability of BMSCs in vitro and in vivo. L-Tryptophan inhibits cell proliferation and induced cell cycle arrest with high levels.
    L-Tryptophan (standard)
  • HY-112166
    Rilzabrutinib 1575596-29-0 98.97%
    Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK), with an IC50 of 1.3 nM.
    Rilzabrutinib
  • HY-139201
    Poly-D-lysine hydrobromide (MW 30000-70000) 27964-99-4
    Poly-D-lysine hydrobromide (MW 30000-70000) is a synthetic polymeric substrate and is one of the most widely used substrate in neural cell culture. Poly-D-lysine hydrobromide is a CaSR agonist peptide.
    Poly-D-lysine hydrobromide (MW 30000-70000)
  • HY-B0575
    Triamterene 396-01-0 99.90%
    Triamterene blocks epithelial Na+ channel (ENaC) in a voltage-dependent manner, which used as a mild diuretic. Triamterene is an inhibitor of the TGR5 receptor.
    Triamterene
  • HY-109120
    Odevixibat 501692-44-0 99.88%
    Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis.
    Odevixibat
  • HY-A0033
    Darifenacin 133099-04-4 99.81%
    Darifenacin (UK-88525) is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin inhibits tumor growth in colorectal cancer cells and has anti-tumor effects.
    Darifenacin
Cat. No. Product Name / Synonyms Application Reactivity